Drupal.behaviors.print = function(context) {window.print();window.close();}>
Integrated Diagnostics Taking Aim at In Vivo Imaging, Therapeutics Markets with New PCC Reagents
October 28, 2011
Integrated Diagnostics Taking Aim at In Vivo Imaging, Therapeutics Markets with New PCC Reagents
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Integrated Diagnostics Forms New Division to House Imaging Business as PCC Development Continues
June 15, 2012 / ProteoMonitor
Agilent Partners with Integrated Diagnostics, Further Signaling Focus on MRM-MS as Clinical Platform
January 13, 2012 / ProteoMonitor
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor
Integrated Diagnostics Secures Additional $10M to Prep for 2013 Launch of Lung Cancer Dx
February 24, 2012 / ProteoMonitor